Kathleen Moore
MD, MS
Associate Director of Clinical Research
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Kathleen Moore is the Virginia Kerley Cade Endowed Chair in Cancer Development and Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center. She currently serves as the Associate Director of Clinical Research and the Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. She also serves as the Associate Program Director of the Gyn Oncology Fellowship Program in the Section of Gyn Oncology of the Department of OB/GYN. She completed her gyn oncology fellowship at the University of Oklahoma Health Sciences Center in 2007 and was recruited to join the faculty. Her primary areas of interest are in new drug development and Phase I clinical trials.

Sessions

Register
General Session

Welcome

Saturday, May 04, 2024
9:00 AM - 9:05 AM
General Session

Session 9: Debate: Does the Restriction in PARPi Use in the Recurrent Setting Justify PARPi for All in the Front Line? - DISCUSSION

Saturday, May 04, 2024
9:35 AM - 9:45 AM
General Session

Session 10: Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum Sensitive Recurrent Disease? - DISCUSSION

Saturday, May 04, 2024
10:15 AM - 10:25 AM
General Session

Session 11: Debate: How Should Novel Agents Be Sequenced in the Platinum Resistant Tumor? - DISCUSSION

Saturday, May 04, 2024
11:25 AM - 11:35 AM
General Session

Session 12: Case Discussions

Saturday, May 04, 2024
11:35 AM - 12:15 PM
General Session

Session 13: Case Discussions

Saturday, May 04, 2024
1:25 PM - 2:05 PM
General Session

Session 14: Debate: Should Immune Checkpoint Inhibitors (ICIs) Be used in all Patients with Locally Advanced Cervical Cancer (LACC) or in Combination with Chemotherapy in the First-Line Metastatic Setting? - DISCUSSION

Saturday, May 04, 2024
2:35 PM - 2:45 PM
General Session

Session 15: Debate: Where Should Antibody Drug Conjugates Be Positioned in Metastatic Endometrial Cancer? - Front Line Opportunity

Saturday, May 04, 2024
3:30 PM - 3:45 PM
General Session

Session 15: Debate: Where Should Antibody Drug Conjugates Be Positioned in Metastatic Endometrial Cancer? - DISCUSSION

Saturday, May 04, 2024
3:45 PM - 3:55 PM
General Session

Session 16: Debate: In What Setting Should Immune Checkpoint Inhibitors (ICIs) Be Incorporated into the Treatment of Endometrial Cancer? - In Any dMMR Endometrial Tumor Regardless of Stage

Saturday, May 04, 2024
3:55 PM - 4:10 PM